Asarina Pharma AB (FRA:APS) Common Stock : €0.49 Mil (As of Jun. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Asarina Pharma AB Common Stock?

Asarina Pharma AB's quarterly common stock declined from Jun. 2022 (€0.53 Mil) to Dec. 2022 (€0.52 Mil) and declined from Dec. 2022 (€0.52 Mil) to Jun. 2023 (€0.49 Mil).

Asarina Pharma AB's annual common stock declined from Dec. 2020 (€0.46 Mil) to Dec. 2021 (€0.46 Mil) but then increased from Dec. 2021 (€0.46 Mil) to Dec. 2022 (€0.52 Mil).

Asarina Pharma AB Common Stock Historical Data

The historical data trend for Asarina Pharma AB's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asarina Pharma AB Common Stock Chart

Asarina Pharma AB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Common Stock

Get a 7-Day Free Trial

0.39

0.44

0.46

0.52

Asarina Pharma AB Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Common Stock	Get a 7-Day Free Trial															0.46	0.45	0.53	0.52	0.49

Asarina Pharma AB Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Asarina Pharma AB (FRA:APS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asarina Pharma AB (FRA:APS) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

ASAP:Sweden

Address

Fogdevreten 2, Karolinska Institutet Science Park, Solna, SWE, SE-171 65

Website

https://www.asarinapharma.com

Asarina Pharma AB is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Its product pipeline is built on over 40 years of research into llopregnanolone-related neurological disorders. With the new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) the company aims to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions.

Asarina Pharma AB (FRA:APS) Headlines

No Headlines